Pharma

Your Article Summary

See Latest Articles

SAR3419 Phase I Study Results in non-Hodgkins Lymphoma at ASH
ImmunoGen, Inc., 12/08/09

ImmunoGen, Inc. , a biopharmaceutical company that develops targeted anticancer therapeutics, announced the presentation of encouraging initial clinical findings with SAR3419 at the American Society of Hematology 51st Annual Meeting and Exposition. Among the findings reported were responses to SAR3419 administered as a single agent among patients with B–cell non–Hodgkin's lymphoma that is refractory to treatment with rituximab.

Today in Conferences/Meetings...keeping you current

Receive free subspecialty "5-minute updates" via email

ARIAD to Present at the Barclays Capital Global Healthcare Conference
ARIAD Pharmaceuticals, 03/16/10

Can Summit help president, Congress find common ground on health care
American Hospital Association News, 03/15/10

Nabi Biopharmaceuticals Announces Date for 2010 Annual Meeting of Shareholders
Nabi Biopharmaceuticals, 03/12/10

 See all of Conferences/Meetings